<DOC>
	<DOC>NCT00808366</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy of RV4104A ointment versus bifonazole-urea ointment for the complete removal of the clinically infected nail plate area in patients with toenail onychomycosis.</brief_summary>
	<brief_title>Efficacy and Safety of RV4104A Ointment in Onychomycosis</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Bifonazole</mesh_term>
	<mesh_term>Keratolytic Agents</mesh_term>
	<criteria>Clinical diagnosis of distallateral or lateral subungual onychomycosis of one great toenail (the target nail) Target nail plate showing â‰¥ 12.5% of clinically infected area Patient must have at least 2 mm of the proximal end of the target nail free of infection Target nail infection due exclusively to a dermatophyte (from both positive direct microscopy examination and positive fungal culture as reported by the central mycological laboratory) Patient with more than 2 affected toenails Patient with psoriasis, lichen planus or other abnormalities that could result in clinically abnormal toenail(s) Patient with moccasintype tinea pedis Patient who has received systemic antifungal therapy or topical antifungal nail lacquer within 3 months or any other topical antifungal therapy applied to the feet or toenails within 2 months prior to screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>